Jazz Gets Second Indication For Xywav As First Therapy For Idiopathic Hypersomnia
Following last year’s approval in cataplexy for the Xyrem follow-on, Jazz could realize additional revenue of up to $500m annually with the first and only approval in IH, analysts say.
You may also be interested in...
The company stopped Phase II clinical trials for TAK-994 to assess a safety signal and determine next steps for the drug, which is viewed as a key product in Takeda’s push for blockbuster revenue growth.
Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.